SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q/A
Amendment No 1.
Quarterly Report under Section 13 or 15 (d) of
Securities Exchange Act of 1934
For Period ended June 30, 2011
Commission File Number 0-32201
BIO-MATRIX SCIENTIFIC GROUP, INC.
(Exact name of registrant as specified in its charter)
DELAWARE | 33-0824714 |
(State of Incorporation) | (I.R.S. Employer Identification No.) |
|
|
4700 Spring Street, Suite 203, La Mesa, California | 91942 |
(Address of Principal Executive Offices) | (Zip Code) |
(619) 398-3517
(Registrant's telephone number, including area code)
Check whether the registrant (1) has filed all reports required to be filed by
Section 13 or 15 (d) of the Securities Exchange Act of 1934 during the preceding
12 months (or for such shorter period that the registrant was required to file
such reports), and (2) has been subject to such filing requirements for the past
90 days. Yes [X] No [ ]
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer,” “non-accelerated filer,” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.
[ ] Large accelerated filer | [ ] Accelerated filer |
|
|
[ ] Non-accelerated filer | [X] Smaller reporting company |
Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Securities Exchange Act of 1934) (check one): Yes [ ] No [X]
There were 72,189,747 shares of Common Stock outstanding as of June 30, 2011.
Pursuant to this Form 10-Q/A, the registrant amends the cover page above for the Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2011 in order to correct a typographical error. No other changes have been made in this Amendment to the Form 10-Q. This Amendment speaks as of the original date of the Form 10-Q, does not reflect events that may have occurred subsequent to the original filing date and does not modify or update in any way disclosures made in the original Form 10-Q. In addition, pursuant to Rule 12b-15 under the Securities Exchange Act of 1934, as a result of this Amended Report, the certifications pursuant to Section 302 and Section 906 of the Sarbanes-Oxley Act of 2002, filed and furnished, respectively as exhibits to the Original Report have been re-executed and re-filed as of the date of this Amended Report and are included as exhibits hereto.
EXHIBITS
31.1 | Certification of Chief Executive Officer |
|
|
31.2 | Certification of Acting Chief Financial Officer |
|
|
32.1 | Certification of Chief Executive Officer under Section 906 of the Sarbanes-Oxley Act of 2002. |
|
|
32.2 | Certification of Acting Chief Financial Officer under Section 906 of the Sarbanes-Oxley Act of 2002. |
2
SIGNATURES
In accordance with the requirements of the Exchange Act, the Company caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Bio- Matrix Scientific Group, Inc. |
| a Delaware corporation |
|
|
By: | /s/ David R. Koos |
| David R. Koos |
| Chief Executive Officer |
|
|
| Date: November 29, 2011 |
3
